Overview

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

Status:
Not yet recruiting
Trial end date:
2022-06-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic (PK), safety, tolerability and immunogenicity of a single subcutaneous (SC) dose of the lyophilized formulation of recifercept in healthy Chinese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer